stand and de-liver, page-20

What sums this company up is the most utterly pathetic comment in an announcement I’ve ever read where in an update a few weeks ago they threw in the line near the end that some Russian scientist ‘urged’ them in to do trials in HIV. That was it: no pre-clinical trial data to support it, no direct mechanistic link, no future trial plans – we’ll just throw into our announcement a statement that is only there to help prop up the company and get investors excited all because of a single comment as by implication it was put there to make people think that Ropren now cures AIDS all based on a conversational anecdote – and to think this company gets called a biotech.

Anyone pick up the comment from Charlie in the BRR interview that in a few weeks the Swinburne study will be sent for publication (but he just couldn’t quite remember the journal’s name it is going to…bit strange don’t you think seeing as BRR interviews are pre-planned with all the questions written by the company). Hang on, isn’t this the same study that none of the results were released from to the market, only sweeping comments of how wonderful it worked, because of IP/patent issues and now it is going to be (allegedly) published? One, or more likely both, of those comments are a down right lie.